Contract manufacturing for cell therapies and biologics with North American scale
Resilience operates a CDMO (contract development and manufacturing organization) focused on cell therapies, biologics, and aseptic manufacturing for biopharma partners. The tech stack reveals heavy process-automation infrastructure—SCADA, Rockwell Automation, SAP, Aveva, Siemens, OSI PI—paired with a manufacturing-dominant hiring mix (47 of 78 open roles) and active adoption of Desigo for facility systems, signaling operational maturity in GMP-regulated environments. Current project velocity centers on manufacturing intelligence, technology transfer, and OEE optimization rather than greenfield platform builds.
Notable leadership hires: FP&A Lead, Lead Investigator
Resilience is a privately held CDMO founded in 2020 and based in Blue Ash, Ohio. The company serves biopharma customers across cell-based therapies, biologics drug substance, and aseptic drug product manufacturing for both small and large molecules. With 1,001–5,000 employees and active hiring in the United States and Canada, Resilience operates manufacturing sites requiring continuous compliance with GMP and cGMP regulations. The operational footprint includes biologics production, device assembly, packaging, and logistics support—each supported by specialized manufacturing execution systems and quality management tools.
Resilience operates SAP, Rockwell Automation, Siemens, AVEVA, OSI PI, and Maximo across its manufacturing and operations infrastructure. SCADA, HMI, and FactoryTalk Batch manage process control in GMP-regulated environments.
Yes. Manufacturing roles represent 47 of 78 active positions. Operations, engineering, and quality also have open roles across mid-, senior-, and director-level seniority.
Resilience actively recruits in the United States and Canada, with headquarters in Blue Ash, Ohio.
Other companies in the same industry, closest in size